Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, China.
The General Hospital of Ningxia Medical University, Ningxia Medical University, Yinchuan, China.
Front Endocrinol (Lausanne). 2023 Jan 23;14:1070264. doi: 10.3389/fendo.2023.1070264. eCollection 2023.
PCOS is a common metabolic disorder in women of reproductive age, which pathogenesis is very complex. The role of ferroptosis in PCOS is a novel finding, and the mechanistic studies are not clear. Metformin is a commonly used drug of PCOS but few studies on whether metformin can improve the follicle development and ovarian function in PCOS. We aims to use PCOS mouse model to study the effect of metformin on PCOS based on the ovarian function and explored the regulation of metformin in PCOS mice by intervening in ferroptosis pathway.
C57 BL/6J female mice aged 4-5 weeks were purchased and gavaged with letrozole (1 mg/kg/day) combined with high-fat diet for 21days to establish PCOS model, and control group was set up. After modeling, the mice were divided into PCOS model group and metformin treatment group (Met) (n=6).The Met group were gavaged metformin (200 mg/kg/day) for 28 days. The body weight, estrous cycle, glucose tolerance test (OGTT)and insulin resistance test (ITT) were monitored. Then, The mice were euthanized to collect serum and ovaries. Elisa was used to detect changes in related serum hormones (E2, LH, FSH, TP). Ovaries used for molecular biology experiments to detect changes in GPX4, SIRT3, AMPK/p-AMPK, and mTOR/p-mTOR by Western blot and qPCR.
Compared with the model group mice, body weight was significantly reduced, and their estrous cycle was restored in Met group. The results of OGTT and ITT showed an improvment of glucose tolerance and insulin resistance. Morphological results showed that after metformin treatment, polycystic lesions in ovaries were reduced, the ovarian function was restored, and the expressions of SIRT3 and GPX4 were elevated. WB results demonstrated that the expressions of p-mTOR and p-AMPK in ovaries were significantly reduced in Model group, but reversed in MET group.
Our study confirmed metformin could not only improve body weight and metabolism disorders, but also improve ovarian dysfunction in PCOS mice.In addition, we explored metformin could regulate ferroptosis to improve PCOS the SIRT3/AMPK/mTOR pathway. Our study complements the mechanisms by which metformin improves PCOS.
多囊卵巢综合征(PCOS)是一种常见的育龄期女性代谢紊乱疾病,其发病机制非常复杂。铁死亡在 PCOS 中的作用是一个新发现,其机制研究尚不清楚。二甲双胍是 PCOS 的常用药物,但关于二甲双胍是否能改善 PCOS 患者的卵泡发育和卵巢功能的研究较少。我们旨在使用 PCOS 小鼠模型,基于卵巢功能研究二甲双胍对 PCOS 的作用,并通过干预铁死亡途径探讨二甲双胍对 PCOS 小鼠的调节作用。
购买 4-5 周龄 C57BL/6J 雌性小鼠,给予来曲唑(1mg/kg/天)联合高脂饮食 21 天建立 PCOS 模型,并设立对照组。造模后,将小鼠分为 PCOS 模型组和二甲双胍治疗组(Met)(n=6)。Met 组灌胃二甲双胍(200mg/kg/天)28 天。监测体重、动情周期、葡萄糖耐量试验(OGTT)和胰岛素抵抗试验(ITT)。然后处死小鼠,收集血清和卵巢。酶联免疫吸附试验(ELISA)检测相关血清激素(E2、LH、FSH、TP)变化。Western blot 和 qPCR 检测卵巢中 GPX4、SIRT3、AMPK/p-AMPK、mTOR/p-mTOR 的变化。
与模型组小鼠相比,Met 组体重明显减轻,动情周期恢复。OGTT 和 ITT 结果表明葡萄糖耐量和胰岛素抵抗得到改善。形态学结果显示,二甲双胍治疗后,卵巢多囊样病变减少,卵巢功能得到恢复,SIRT3 和 GPX4 表达升高。WB 结果显示,模型组卵巢中 p-mTOR 和 p-AMPK 的表达明显降低,但在 MET 组中逆转。
本研究证实二甲双胍不仅能改善体重和代谢紊乱,还能改善 PCOS 小鼠的卵巢功能。此外,我们还探索了二甲双胍可以通过调节铁死亡来改善 PCOS 中的 SIRT3/AMPK/mTOR 通路。我们的研究补充了二甲双胍改善 PCOS 的机制。